EP
ALT icon

Eversept Partners’s Altimmune ALT Stock Holding History

Eversept Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-380,000
Closed -$4.29M – 86
2020
Q4 		$4.29M Buy
+380,000
New +$4.48M 0.5% 36

Other funds holding ALT

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Eversept Partners's ALT Position: Q1 2021 in Review

Eversept Partners sold out of Altimmune (ALT) in Q1 2021, closing a stake of 380,000 shares — an estimated $4.29M sold.

Eversept Partners first reported a position in ALT in Q4 2020 and held it in 1 quarter. The position peaked at $4.29M in Q4 2020. 96 funds tracked by Wall St. Rank hold ALT as of Q1 2021.

  • Eversept Partners reported no remaining Altimmune position as of Q1 2021 after selling out during the quarter.
  • Eversept Partners sold 380,000 Altimmune shares in Q1 2021, an estimated $4.29M.
  • Eversept Partners first reported a position in Altimmune in Q4 2020 and held it in 1 quarter.
  • Eversept Partners's Altimmune position peaked at $4.29M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Altimmune as of Q1 2021.

Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.